<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian R Wood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul E Sax, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2498599584">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For persons with human immunodeficiency virus (HIV) who have a stably suppressed plasma viral load (eg, HIV RNA below the limit of detection for at least 6 to 12 months) on antiretroviral therapy (ART), the patient and clinician may consider switching the ART regimen because of factors such as side effects or pill burden. In this setting, the goal is to maintain virologic suppression while improving the patient's quality of life and reducing the risk of short- or long-term toxicity. This is distinct from the situation of virologic failure, in which a salvage regimen must be crafted because of poor adherence and virologic rebound, with or without drug resistance.
        </p>
        <p>
         This topic will describe the approach to making a regimen switch in the setting of virologic suppression in patients with HIV-1 infection. Topic reviews that discuss changing a regimen in the setting of virologic failure are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13975.html" rel="external">
          "Evaluation of the treatment-experienced patient failing HIV therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">
          "Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1172609620">
         <span class="h1">
          REASONS FOR CHANGING A REGIMEN
         </span>
        </p>
        <p class="headingAnchor" id="H1649321588">
         <span class="h2">
          Tolerability of current regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several reasons why patients who are virologically suppressed may benefit from a switch of their antiretroviral therapy (ART) regimen. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pill burden
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-drug interactions
        </p>
        <p>
        </p>
        <p>
         In a study of 246 patients who changed ART between January 2011 and July 2012, the most common reasons were toxicity and regimen simplification [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Other reasons might include new or worsening medical comorbidities (eg, chronic kidney disease), cost issues or changes in insurance, desire to match a partner's regimen, difficulty with food requirements, desire to conceive, or pregnancy. Considerations for regimen selection in these settings are discussed below. (See
         <a class="local">
          'Other considerations for regimen selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3984719969">
         <span class="h2">
          Risk of long-term complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients may be tolerating their regimen but are at risk for long-term toxicity with the antiretroviral agents they are receiving.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients receiving TDF
         </strong>
         – For patients with normal renal function, we have a low threshold to switch patients off of
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) to reduce the risk of TDF-associated nephrotoxicity. This is particularly important for patients who have risk factors for renal disease (eg, diabetes), are over 50 years of age, and/or take other nephrotoxic medications. Options typically consist of switching TDF to
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF) or using a tenofovir-sparing regimen, as discussed below. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         below and
         <a class="local">
          'Kidney disease not related to ART'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For some patients, insurance may not cover TAF-based options. If this is the case and the person has normal renal function and none of the risk factors mentioned above for TDF-associated renal disease, we continue the TDF-based option with regular monitoring for renal adverse effects (see
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy"
         </a>
         ). If a person taking TDF has abnormal renal function and/or significant risk factors for TDF-associated renal disease, we petition insurance for the TAF-based option.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of TDF plus a boosted protease inhibitor (PI) carries a higher risk of TDF-induced renal toxicity than other combinations; so, for patients with risk factors for renal disease, we often change the boosted PI and TDF if the change can be done safely [
         <a href="#rid2">
          2-4
         </a>
         ]. As an example, if a patient has multiple risk factors for renal disease and is taking TDF-emtricitabine plus a boosted PI, we often switch TDF to TAF and/or the boosted PI to
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir (recognizing that the switch to dolutegravir or bictegravir may lead to a mild increase in serum creatinine after the regimen change). If these agents cannot be changed, we continue careful renal monitoring. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy", section on 'ART-associated toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also have a low threshold to switch patients from TDF to TAF to reduce the risk of TDF-associated bone disease. This may be particularly beneficial for individuals with osteopenia or multiple risk factors for osteoporosis (eg, low body weight, tobacco smoking, family history of osteoporosis). (See
         <a class="local">
          'Osteopenia/osteoporosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to inform patients that they may experience weight gain following a switch from TDF to TAF, although the mechanism and cardiometabolic implications of this are unclear. (See
         <a class="local">
          'Risk of weight gain'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients receiving
         </strong>
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         – For patients with ischemic cardiovascular events, we always change abacavir since abacavir may raise the risk of ischemic cardiovascular disease [
         <a href="#rid5">
          5-10
         </a>
         ]. For a patient at high risk of cardiovascular disease, we also prefer to change abacavir to TAF or another option if there are no contraindications. (See
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV", section on 'Role of antiretroviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Elvitegravir-containing regimens
         </strong>
         – If a patient is taking an elvitegravir-containing regimen (eg, elvitegravir-cobicistat-emtricitabine-TDF or elvitegravir-cobicistat-emtricitabine-TAF) and the regimen is well tolerated with a routinely suppressed viral load, it is not necessary to change to a different option. However, we have a low threshold to make a change because other regimens tend to have fewer side effects and drug-drug interactions. In addition, the boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         options have a relatively low barrier to resistance, and virologic failure on one of the boosted elvitegravir options can lead to significant multiclass drug resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals taking one of these elvitegravir-containing regimens, we regularly assess tolerability (especially gastrointestinal symptoms) and drug-drug interactions (including with over-the-counter medications), and we emphasize the importance of adherence to daily dosing. If any issues are apparent, we switch to a regimen that includes an unboosted integrase strand transfer inhibitor (INSTI) with a high barrier to resistance, such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir. (See
         <a class="local">
          'Choosing a regimen'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs;
         </strong>
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         <strong>
          )
         </strong>
         – If a patient has a suppressed viral load on efavirenz, we inquire about depression and other mental health and central nervous system (CNS) side effects. We then adjust the regimen if these symptoms are present. (See
         <a class="local">
          'Neuropsychiatric side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the patient is tolerating
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         , it is not essential to change the medication, although we have a low threshold to recommend a change because newer regimens have a higher barrier to resistance and tend to be better tolerated. Patients may feel better after a change of therapy even if they did not report significant pre-switch side effects with efavirenz. The change also may benefit lipids and vitamin D levels. (See
         <a class="medical medical_review" href="/z/d/html/3738.html" rel="external">
          "Bone and calcium disorders in patients with HIV", section on 'Vitamin D'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar to
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         , a change in regimen is not necessary in virologically suppressed patients taking
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         so long as they are tolerating the regimen. However, we discuss the potential advantages of an update (newer options have a higher barrier to resistance and may also provide a slightly lower pill burden). For those considering a switch, we do discuss the potential risk of serious immune-mediated toxicity if nevirapine should be resumed, especially for those with a high CD4 count (&gt;250 cells/microL for females, &gt;400 cells/microL for males), as discussed below. (See
         <a class="local">
          'Can a patient resume a prior regimen'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If a patient wants to stay on
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         and is taking it twice daily, updating to the extended-release, once-daily version is also an option. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Nevirapine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Older nucleoside reverse transcriptase inhibitors (NRTIs) or older PIs
         </strong>
         – There are certain antiretroviral agents that we always try to change because of increased long-term risk of metabolic and other toxicities. These include older NRTIs (eg,
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         ) or older PIs such as
         <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">
          lopinavir-ritonavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8634" href="/z/d/drug information/8634.html" rel="external">
          fosamprenavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">
          indinavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">
          nelfinavir
         </a>
         , or
         <a class="drug drug_general" data-topicid="9877" href="/z/d/drug information/9877.html" rel="external">
          saquinavir
         </a>
         . Changing these older antiretroviral drugs to newer options also reduces pill burden.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those receiving boosted
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         , the decision to switch agents is less clear. Guideline panels no longer recommend boosted atazanavir as a first-line treatment option because of reduced tolerability compared with newer agents [
         <a href="#rid11">
          11-13
         </a>
         ]; in addition, atazanavir is associated with unique side effects such as indirect hyperbilirubinemia (which can lead to jaundice), kidney stones, and gallstones. However, it is not essential to change the medication if there are no tolerability issues. Atazanavir is also the only boosted PI that is not linked to a higher risk of cardiovascular events, and it may actually reduce cardiovascular risk since it causes elevated bilirubin levels and bilirubin is an antioxidant [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions", section on 'Cardiovascular disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3644599064">
         <span class="h2">
          Regimen has a low barrier to resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients may be tolerating their regimen, but it has a relatively low barrier to resistance (this includes NNRTI-based regimens or regimens with
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         or boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         plus two NRTIs). We do not always switch regimens in this setting. However, we carefully assess adherence and drug-drug and drug-food interactions, and if any appear problematic, we recommend switching to an option with a relatively higher barrier to resistance (usually dolutegravir- or bictegravir-based therapy or sometimes a boosted darunavir-based option). (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3726310809">
         <span class="h1">
          EVALUATION PRIOR TO SWITCHING REGIMENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         When switching a regimen, the goal is to maintain a suppressed plasma viral load (HIV RNA) while improving the patient's quality of life and reducing the risk of short- or long-term toxicity. To determine if this is feasible, it is important to evaluate the patient's antiretroviral history (especially history of any virologic failures, antiretroviral drug resistance, or antiretroviral drug intolerances), comorbid conditions, and barriers to taking the current regimen. Every discussion about switching antiretroviral therapy (ART) should include an explanation of the potential risks and benefits as well as a discussion of the potential to resume the pre-switch regimen if unanticipated side effects occur. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         below and
         <a class="local">
          'Other considerations for regimen selection'
         </a>
         below and
         <a class="local">
          'Can a patient resume a prior regimen'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4255053366">
         <span class="h1">
          ENSURING THE POTENCY OF THE NEW REGIMEN
         </span>
        </p>
        <p class="headingAnchor" id="H1827407493">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         For a patient who has a suppressed viral load, switching antiretroviral therapy (ART) can involve a single- or multi-drug switch. In either case, it is important to ensure that the new regimen will maintain virologic suppression. The likelihood that a patient will maintain virologic suppression depends upon:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of prior resistance mutations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the new regimen has a relatively high or low barrier to resistance; this is particularly important if the switch involves a change from a regimen with a higher barrier to resistance to a regimen with a lower barrier to resistance (which carries more risk) or a switch to a regimen with fewer active drugs.
        </p>
        <p>
        </p>
        <p>
         A regimen with a relatively high barrier to resistance includes a boosted protease inhibitor (PI) or the integrase inhibitors
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir as the third agent. Most other regimens (eg, those that include
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         , or
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         as the third agent) have a lower barrier to resistance.
        </p>
        <p>
         If switching from a regimen with a high-resistance barrier to a regimen with a low barrier, it is essential to ensure that there are no resistance mutations that could compromise the activity of the nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone. This was demonstrated in the SWITCHMRK 1 and 2 trials, in which participants with suppressed HIV RNA levels taking ritonavir-boosted lopinavir plus two NRTIs either continued their current regimen or switched to
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         plus two NRTIs [
         <a href="#rid15">
          15
         </a>
         ]. These trials were halted at week 24 because fewer participants in the switch arm maintained virologic suppression and results failed to meet noninferiority criteria. However, in an analysis limited to participants with no history of virologic failure or NRTI-associated resistance mutations, those who switched to raltegravir maintained virologic suppression at a rate noninferior to those who continued the boosted PI.
        </p>
        <p>
         Some providers may be concerned about switching to
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         if the pretreatment HIV RNA was above 100,000 copies/mL or the CD4 count was below 200 cells/microL since rilpivirine should not be used in such patients who are treatment naïve. However, we generally feel comfortable changing to a rilpivirine-containing ART option if the patient has had no prior virologic failures or significant NRTI or non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations and the viral load is suppressed at the time of the switch. Clinical trial data suggest that a switch to rilpivirine is safe in this setting [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Single-drug regimens should
         <strong>
          not
         </strong>
         be used, as studies have demonstrated an increased risk of virologic failure with monotherapy, even with drugs that have a high barrier to resistance (eg, ritonavir-boosted PIs or
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ) [
         <a href="#rid11">
          11,17-20
         </a>
         ]. As an example, in a randomized trial of 158 patients with virologic suppression on
         <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">
          dolutegravir-abacavir-lamivudine
         </a>
         , the cumulative incidence of virologic breakthrough (viral load &gt;50 copies/mL on two occasions) was 9.7 percent over 48 weeks in those who switched to dolutegravir monotherapy, and two patients developed integrase strand transfer inhibitor (INSTI) resistance; by contrast, patients who stayed on dolutegravir-abacavir-lamivudine remained virologically suppressed [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3359600591">
         <span class="h2">
          Evaluating for prior resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         To assess for prior resistance, it is important to know whether the patient has experienced past instances of virologic failure and if there is a history of documented antiretroviral drug-resistance mutations (either pretreatment or secondary to virologic failure).
        </p>
        <p>
         A composite of past RNA genotypes is the preferred method for assessing resistance. However, a common clinical challenge arises when past resistance results are not available or if the test was performed when the patient was not taking ART (resistance testing may not detect all the viral mutations if the patient has not taken medications for more than four weeks or so). In this setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We review the patient's past ART regimens and viral load results as best we can to determine if resistance mutations are likely. We consider individuals to have suspected resistance if they switched ART because of virologic rebound on their prior regimen, received previous suboptimal ART (eg, mono- or dual-NRTI regimens), or have a suppressed HIV RNA level on what appears to be a salvage regimen but have an unknown resistance mutation history. A discussion of salvage regimens is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">
          "Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy", section on 'Patients who have failed multiple regimens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We also assess if obtaining a proviral DNA ("archive") genotype test would be helpful since traditional RNA genotypes are not feasible with a suppressed HIV RNA. If past RNA genotype results are not available, we consider checking a proviral DNA genotype, particularly for patients who take a complex salvage ART regimen, who have taken multiple past regimens, and who wish to simplify ART to fewer active drugs or a combination with a relatively lower barrier to resistance [
         <a href="#rid11">
          11
         </a>
         ]. This test can detect resistance mutations in proviral HIV DNA archived within peripheral blood mononuclear cells and may provide clinically useful information to help guide ART changes [
         <a href="#rid21">
          21,22
         </a>
         ]. However, the best use of this test remains unclear since results often do not show complete concordance with traditional RNA genotypes and may either miss historical mutations or detect mutations not present on RNA genotyping (these are of unclear clinical significance) [
         <a href="#rid11">
          11,23-26
         </a>
         ]. Loss of information on DNA genotyping has been associated with longer duration of ART usage [
         <a href="#rid27">
          27,28
         </a>
         ]. Additional information on proviral DNA assays is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3769.html" rel="external">
          "Overview of HIV drug resistance testing assays", section on 'HIV-1 proviral DNA assays'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3948712923">
         <span class="h2">
          Choosing a regimen
         </span>
        </p>
        <p class="headingAnchor" id="H141162903">
         <span class="h3">
          Patients with no history of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient has no history of resistance-associated mutations, we generally switch to any of the preferred ART regimens after a review of comorbid conditions, drug-drug interactions, potential side effects, food requirements, and insurance access; alternative treatment options include
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         , raltegravir-, or rilpivirine-based regimens  (
         <a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef130164" href="/z/d/graphic/130164.html" rel="external">
          table 2
         </a>
         ). In this setting, in which we feel confident there is no resistance that will compromise the new regimen (especially the NRTI combination), we are comfortable with a switch to a regimen with a greater, equal, or lower barrier to resistance. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient reports central nervous system (CNS) or mental health side effects while taking
         <a class="drug drug_general" data-topicid="8858" href="/z/d/drug information/8858.html" rel="external">
          efavirenz-emtricitabine-tenofovir disoproxil fumarate
         </a>
         (a regimen with relatively low barrier to resistance), we feel comfortable switching to any of the preferred regimens or to raltegravir-, rilpivirine-, or doravirine-based ART, assuming the viral load is suppressed and there are no other contraindications (since these regimens have a similar barrier to resistance). Considerations for regimen selection in the setting of neuropsychiatric side effects are presented below. (See
         <a class="local">
          'Neuropsychiatric side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient taking a regimen with a relatively high barrier to resistance (eg,
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         or cobicistat-boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus two NRTIs) needs to change regimens because of potential drug interactions, but has had past ART regimen switches, we generally prefer switching to a new regimen with a similarly high barrier to resistance (such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir-based therapy). If this is not possible, we would feel comfortable switching to a regimen with a lower barrier to resistance (eg,
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         , or elvitegravir-based therapy) only if it is well documented that the viral load remained suppressed through all of the switches. If it is not clear whether this is the case, a DNA (archive) genotype should be obtained before making the switch. The approach to treatment in patients with suspected drug resistance is described below. (See
         <a class="local">
          'Patients with known or suspected drug resistance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         For certain patients with stable HIV RNA suppression (eg, at least 6 to 12 months), a two-drug regimen may be an option if there are concerns about toxicity or pill burden and one of the preferred three-drug regimens cannot be used. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1044873296">
         <span class="h3">
          Patients with known or suspected drug resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have a suppressed viral load (HIV RNA) and have known or suspected resistance, we typically switch their regimen only if we are able to create one that has an equal or greater barrier to resistance. We determine if a patient has known resistance by reviewing past resistance test results, and we determine if a patient has suspected antiretroviral resistance by reviewing past regimens and viral load results for evidence of episodes of virologic failure; this is discussed in greater detail above. (See
         <a class="local">
          'Evaluating for prior resistance'
         </a>
         above.)
        </p>
        <p>
         For patients with known or suspected resistance, selecting a new regimen depends upon the type and number of prior resistance mutations and available active agents. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient with known NRTI resistance has a suppressed HIV RNA on a regimen such as
         <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">
          tenofovir alafenamide-emtricitabine
         </a>
         plus boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         but is bothered by side effects associated with the boosted PI, the patient could continue the NRTI combination, and the boosted PI could be switched to the INSTI
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir. This switch would not significantly change the relative barrier to resistance and is generally effective as long as the patient has at least one active NRTI and there is no history of INSTI resistance. However, in this scenario, we would
         <strong>
          n
         </strong>
         ot switch to a third agent of relatively lower barrier to resistance, such as
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         , or boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         , without adding additional active agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with NRTI mutations who are virologically suppressed on a PI-based regimen are able to switch to a dolutegravir- or bictegravir-containing regimen and maintain virologic control [
         <a href="#rid29">
          29-33
         </a>
         ]. In a randomized trial of 795 patients with HIV who were on a second-line regimen after failing an initial NNRTI-containing regimen, switching from a boosted PI to
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         was effective, even without knowledge of prior resistance [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, a single-drug switch may not be feasible in a patient with multi-class resistance who is taking agents from several different classes. In this setting, we generally switch multiple agents to craft a regimen with at least three active drugs (or at least two active drugs if a boosted PI or
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir can be included). To help ensure the potency of a new regimen, patients with a history of complex drug resistance who are virologically suppressed should preferably have their regimens switched only in consultation with an HIV specialist.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H69778317">
         <span class="h3">
          Eligibility for two-drug regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two-drug regimens may be suitable for certain virologically suppressed patients who have developed or are at risk of developing toxicity from NRTIs like
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF),
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF), and
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         [
         <a href="#rid34">
          34-36
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eligibility
         </strong>
         – Prior to switching to a two-drug regimen:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We ensure there are no drug-resistance mutations that would compromise either agent in the two-drug option. If records are not available or the resistance history is not clear and the patient must change regimens (eg, due to toxicity), obtaining a proviral DNA ("archive") genotype is reasonable. (See
         <a class="local">
          'Evaluating for prior resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When considering two-drug oral ART, we ensure that at least one of the agents in the two-drug regimen has a high barrier to resistance (eg,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         ). (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We confirm that there are no significant drug-drug interactions that might reduce the concentration of either drug. (See
         <a class="local">
          'Reducing drug-drug and drug-food interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We confirm there is no evidence of chronic hepatitis B virus (HBV) infection (TDF or TAF should be part of the ART regimen in patients with chronic HBV). (See
         <a class="local">
          'Chronic HBV infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred regimens
         </strong>
         – Once-daily options for two-drug maintenance ART include
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         and
         <a class="drug drug_general" data-topicid="115773" href="/z/d/drug information/115773.html" rel="external">
          dolutegravir-rilpivirine
         </a>
         (both available as single, coformulated tablets) as well as the long-acting injectable regimen
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         (
         <a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">
          table 3
         </a>
         ). Of the oral two-drug options, we generally prefer dolutegravir-lamivudine because it avoids the full meal requirement and added drug-drug interactions of dolutegravir-rilpivirine, but both are suitable options to replace three-drug oral ART for select patients who have long-term virologic suppression and no hepatitis B coinfection, as described above. The decision to use injectable versus oral therapy and details regarding administration of cabotegravir-rilpivirine are presented below and in a separate topic review. (See
         <a class="local">
          'Long-acting injectable therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/138435.html" rel="external">
          "Use of long-acting cabotegravir-rilpivirine in people with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several clinical trials have supported the use of
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         as maintenance therapy [
         <a href="#rid37">
          37-40
         </a>
         ]. As an example, in an open-label randomized trial of 743 patients with a plasma HIV RNA &lt;50 copies/mL for at least six months, participants who switched to dolutegravir-lamivudine maintained virologic suppression at a rate similar to those who continued a three- or four-drug TAF-containing regimen at 48 weeks [
         <a href="#rid40">
          40
         </a>
         ]. Participants had no history of INSTI or NRTI resistance or virologic failure requiring a change in regimen, no evidence of virologic failure within one year of switching regimens, and no evidence of hepatitis B coinfection. In this trial, there were improvements in certain metabolic parameters (total and low-density lipoprotein [LDL] cholesterol, triglycerides, insulin resistance) in those who switched to dolutegravir-lamivudine, but these results were largely driven by participants receiving regimens with pharmacokinetic boosters (in particular, elvitegravir-cobicistat-emtricitabine-TAF) at baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of
         <a class="drug drug_general" data-topicid="115773" href="/z/d/drug information/115773.html" rel="external">
          dolutegravir-rilpivirine
         </a>
         was supported by the open-label SWORD-1 and SWORD-2 trials [
         <a href="#rid41">
          41
         </a>
         ]. In these trials, 1028 individuals taking a standard three-drug ART regimen were randomized to either continue current therapy or simplify to
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         . Subjects were required to have a suppressed HIV RNA for at least six months prior to the switch, be taking their first or second ART regimen only, and have no history of virologic failure or hepatitis B coinfection. The proportion of participants in the two-drug maintenance arm with suppressed HIV RNA at 48 weeks was similar to those on the three-drug ART arm (95 percent in both arms; adjusted treatment difference of -0.2 percent [95% CI -3.0 to 2.5 percent]). Observational and retrospective studies have also demonstrated that carefully selected treatment-experienced individuals can safely simplify their regimen to dolutegravir-rilpivirine dual maintenance therapy [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several clinical trials have supported the use of long-acting injectable therapy with
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         . These are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/138435.html" rel="external">
          "Use of long-acting cabotegravir-rilpivirine in people with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative regimens
         </strong>
         – There is limited experience using two-drug combinations that include a boosted PI. The combination of ritonavir-boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         was evaluated in 249 patients with an HIV RNA &lt;50 copies/mL for at least six months on a three-drug regimen that included ritonavir-boosted darunavir plus two NRTIs [
         <a href="#rid44">
          44
         </a>
         ]. At 48 weeks, the proportion of participants with a suppressed viral load was 90 percent in those randomized to dual therapy and 93 percent in those randomized to continue triple therapy (difference -3.8 percent; 95% CI -11.0 to 3.4). Other studies have also supported the use of ritonavir-boosted
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         or
         <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">
          lopinavir-ritonavir
         </a>
         with lamivudine; however, these PIs are generally not as well tolerated as boosted darunavir [
         <a href="#rid45">
          45-47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A switch to the two-drug combination boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         was compared with continuation of boosted darunavir plus two NRTIs in a randomized, open-label trial of 263 individuals with an HIV RNA level below 50 copies/mL for at least 24 weeks and no hepatitis B infection [
         <a href="#rid48">
          48
         </a>
         ]. After 48 weeks, those who switched to the two-drug regimen maintained a suppressed viral load at a similar rate as the group who continued their three-drug combination (86.3 versus 87.9 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other two-drug combinations, such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         and boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus doravirine or
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         , may be considered in select situations when the above regimens cannot not be used [
         <a href="#rid49">
          49-52
         </a>
         ], but these have not been well studied.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4047536679">
         <span class="h1">
          OTHER CONSIDERATIONS FOR REGIMEN SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This section will discuss factors to consider when switching to a new antiretroviral therapy (ART) regimen in nonpregnant adults and adolescents. Specific considerations during pregnancy are discussed below and in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">
          "Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'ART selection and management'
         </a>
         .)
        </p>
        <p>
         In general, it is best to switch to the new regimen and not interrupt or discontinue therapy. A discussion of how to ensure the potency of a new regimen is discussed above. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1973706298">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         When changing a regimen due to intolerance, it is important to understand the types and severity of side effects the patient is experiencing. We assess the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a specific agent in the regimen is most likely to be causing the side effects
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If an agent less likely to cause the side effects can be substituted for the offending agent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is a benefit to replacing or updating more than one agent in the regimen
        </p>
        <p>
        </p>
        <p>
         Side effects are frequent reasons for modifying an ART regimen and can often be managed by single-drug substitutions. However, newer ART regimens, such as those that include unboosted integrase inhibitors, are generally better tolerated and require fewer treatment modifications compared with other options [
         <a href="#rid53">
          53,54
         </a>
         ]. In addition,
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF) is associated with reduced nephrotoxicity compared with
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF), and ritonavir-boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         is generally better tolerated than other protease inhibitors (PIs), including boosted
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2920975599">
         <span class="h3">
          Gastrointestinal intolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal (GI) side effects may occur with any antiretroviral agent, but among the commonly used drugs, PIs and pharmacokinetic boosters (ie,
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ) are the most likely causes. We have occasionally seen GI intolerance with TDF. GI side effects with other agents are much less common.
        </p>
        <p>
         For patients taking a boosting agent (usually a ritonavir- or cobicistat-boosted PI or cobicistat-boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ), GI symptoms and signs may improve with a switch to a nonboosted integrase strand transfer inhibitor (INSTI), such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir. For patients who are already taking an unboosted INSTI, careful consideration should be given to possible nonantiretroviral causes for the GI symptoms before changing the regimen. If an acid suppressing agent is required, drug-drug interactions should be assessed. (See
         <a class="local">
          'Reducing drug-drug and drug-food interactions'
         </a>
         below.)
        </p>
        <p>
         Occasionally, a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen may be considered in patients with GI intolerance, but several factors should be reviewed before making this change. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1070775166">
         <span class="h3">
          Neuropsychiatric side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antiretroviral agent that most frequently causes neuropsychiatric adverse effects is
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ]. The non-nucleoside reverse transcriptase inhibitor (NNRTI)
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         and the INSTIs (especially
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ) can also cause central nervous system (CNS) side effects but are less likely to do so. A more detailed description of these adverse reactions is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Integrase strand transfer inhibitors (INSTIs)'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NNRTIs
         </strong>
         – We generally have a low threshold to switch
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         to a different agent to improve CNS side effects. This is particularly important for patients with depression, as efavirenz use has been associated with an increased risk of suicidal ideation [
         <a href="#rid55">
          55
         </a>
         ]. Mental health side effects frequently diminish with a switch from efavirenz to an INSTI, such as
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         , or bictegravir or to another NNRTI, such as
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         or
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies that compared
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         with an INSTI or with
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         generally found fewer CNS side effects with the nonefavirenz-based option [
         <a href="#rid56">
          56-60
         </a>
         ]. In addition, switching from efavirenz to one of these agents can lead to resolution of CNS manifestations [
         <a href="#rid61">
          61-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          INSTIs
         </strong>
         – Although
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         is the antiretroviral agent most commonly associated with CNS side effects, 5 to 10 percent of patients do not tolerate
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         . Multiple studies have found that dolutegravir can cause insomnia, headache, and other CNS symptoms [
         <a href="#rid65">
          65-70
         </a>
         ]. There are also rare reports of severe depression with the INSTIs
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         and dolutegravir, and it has been suggested that the neuropsychiatric side effects may be a class effect of the integrase inhibitors in some individuals [
         <a href="#rid71">
          71-73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are limited data to guide treatment decisions in these settings. For those with severe mental health side effects, we switch from an INSTI-containing regimen to one that includes a third agent from a different class (eg, the NNRTI
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         if there are no concerns for resistance). In contrast, for those with milder adverse reactions (eg, insomnia or headache), we usually try to switch to a different INSTI. Although some patients may ultimately require a switch to a different antiretroviral class, in our experience mild CNS symptoms sometimes resolve after switching
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         to an INSTI like bictegravir.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2042541767">
         <span class="h3">
          Transaminitis/hepatic events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations that occur secondary to ART are mild and asymptomatic, and many improve or remain stable without modification of ART. Severe hepatotoxicity occurs rarely and generally occurs before the patient has a stably suppressed viral load. In a cohort of over 10,000 individuals with HIV, significant elevation in aminotransferase levels occurred within one year of starting ART in 2 percent [
         <a href="#rid74">
          74
         </a>
         ]. Thus, for patients stably suppressed on an ART regimen, it is important to consider other causes of transaminase flares (alcohol, nonantiretroviral medication-induced, nonalcoholic fatty liver disease, hepatitis C or hepatitis C immune reconstitution inflammatory syndrome, and other etiologies). (See
         <a class="medical medical_review" href="/z/d/html/3729.html" rel="external">
          "Evaluation of the patient with HIV and hepatobiliary complaints"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H654649469">
         <span class="h3">
          Weight gain
         </span>
        </p>
        <p class="headingAnchor" id="H1607934224">
         <span class="h4">
          Risk of weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         ART regimens that include TAF and/or an INSTI (especially
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ) are associated with greater increases in weight as compared with other classes or agents; this association with greater weight change has been demonstrated after a regimen switch, such as from an NNRTI to an INSTI or from TDF to TAF [
         <a href="#rid75">
          75-84
         </a>
         ].
        </p>
        <p>
         For individuals switching to TAF or an INSTI from an older agent, we counsel about the potential for weight gain and the importance of healthy eating and exercise, and we monitor weight and metabolic parameters. In general, we do not see this issue as a reason to avoid TAF or INSTIs, but decisions for patients should be individualized, particularly for those who also have metabolic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         .)
        </p>
        <p>
         The weight increase after a switch of ART generally occurs early after the switch and stabilizes by approximately 48 weeks after the switch for most individuals [
         <a href="#rid79">
          79
         </a>
         ]. Greater likelihood of weight gain has also been associated with certain social determinants of health and demographic factors, such as Black race and female gender [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         The mechanism and long-term cardiometabolic consequences of weight change between different antiretrovirals have not been confirmed. The difference in weight change between TDF and TAF appears to stem from weight suppressive effects of TDF. Studies have not established that TAF directly causes weight gain, and in clinical trials, individuals who stop TDF gain weight even in the absence of a switch to TAF [
         <a href="#rid40">
          40,85
         </a>
         ]. Other NRTIs, such as
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         and
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         , may also suppress weight, and individuals tend to gain weight after a switch from one of these agents to TAF as well [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         There may be an INSTI class effect that impacts weight and/or glycemic control [
         <a href="#rid86">
          86
         </a>
         ]. Although most studies have found an association between
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir and weight gain after switching from an NNRTI or PI [
         <a href="#rid76">
          76,80,83
         </a>
         ], some have implicated
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         or boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         as well. INSTI usage may also lead to an excess risk for diabetes or cardiovascular disease, but these effects and predictors of such effects for individual patients have not been fully elucidated [
         <a href="#rid87">
          87,88
         </a>
         ]. Further research to better understand and confirm the cardiometabolic effects of INSTIs is needed. In the meantime, the possible association between INSTIs and such comorbidities must be weighed against evidence that INSTIs demonstrate greater long-term durability, tolerability, and virologic suppression rates compared to agents from other classes. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H782152631">
         <span class="h4">
          Managing weight gain on ART
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who experience substantial weight gain on TAF or an INSTI, it is unclear if changing TAF and/or the INSTI will lead to reversal of the weight change. It is also unclear whether returning to an alternate agent that may have weight suppressive effects (eg, TDF or an NNRTI) is better for an individual's health or not. In cases in which weight gain while taking TAF and/or an INSTI has occurred, we emphasize lifestyle modifications for weight loss and discuss the pros and cons of switching therapy.
        </p>
        <p>
         If a person has a suppressed viral load while taking
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir with TAF-emtricitabine, yet weight gain on the regimen has caused or contributed to mental distress or medical complications (such as glucose intolerance, hypertension, or cardiovascular disease), we consider switching to an NNRTI with TAF-emtricitabine or TDF-emtricitabine (as long as these agents are fully active) but counsel that it is not clear that this will reverse the weight gain, the NNRTI-based regimen has a relatively lower barrier to resistance, and the new regimen may have other potential adverse effects. Clinical trials to help guide clinicians and patients about these options and optimal ART management following INSTI and TAF-associated weight gain are ongoing.
        </p>
        <p class="headingAnchor" id="H1565445394">
         <span class="h3">
          Mitochondrial toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older NRTIs, such as
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         , can cause significant mitochondrial toxicity, leading to pancreatitis, lipoatrophy, lactic acidosis, and other adverse events. We always try to switch these agents. In rare instances, zidovudine may be used to maintain viral suppression (such as with the K65R NRTI resistance mutation, which increases zidovudine susceptibility); however, even in this setting, there are usually enough other agents available that zidovudine can be switched to a better-tolerated option. (See
         <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">
          "Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3933681802">
         <span class="h2">
          Comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may have certain comorbid conditions that require a change in or impact selection of their ART regimen. These conditions may have been present prior to initiating ART (eg, hepatitis B virus [HBV] infection), have resulted from their ART regimen (reduced kidney function due to TDF), or have developed due to other causes (eg, reduced kidney function due to diabetes).
        </p>
        <p class="headingAnchor" id="H902801774">
         <span class="h3">
          Reduced kidney function
         </span>
         <span class="headingEndMark">
          —
         </span>
         When switching a regimen in patients with or at risk for reduced kidney function, it is important to consider if the patient's current antiretroviral regimen is the cause of the kidney disease.
        </p>
        <p class="headingAnchor" id="H1579943550">
         <span class="h4">
          Renal events due to ART regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         TDF is the antiretroviral agent that most frequently causes nephrotoxicity (eg, proximal tubule wasting) [
         <a href="#rid2">
          2-4
         </a>
         ], although
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         has also been associated with adverse renal events (eg, kidney stones). (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir disoproxil fumarate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Atazanavir'
         </a>
         .)
        </p>
        <p>
         If renal toxicity develops with one of these agents, it should be changed. For patients who develop TDF-associated proximal tubulopathy, we use the following approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without chronic HBV
         </strong>
         – For patients
         <strong>
          without
         </strong>
         chronic HBV, the regimen can be switched to a two-drug regimen that does not include tenofovir (TDF or TAF). As an example, if a person who has a suppressed HIV RNA level and no history of virologic failures or resistance develops TDF-induced renal toxicity, a switch to a maintenance regimen such as
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="115773" href="/z/d/drug information/115773.html" rel="external">
          dolutegravir-rilpivirine
         </a>
         may be an option (see
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above). However, if the patient is taking a more complex regimen when TDF-associated proximal tubulopathy occurs, TDF may need to be replaced with an alternate agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally avoid switching to TAF while the patient is experiencing acute renal dysfunction related to TDF. Although TAF is associated with less renal toxicity and switching to TAF may be safe [
         <a href="#rid89">
          89,90
         </a>
         ], there is limited experience using TAF in the setting of active TDF-induced renal dysfunction [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with chronic HBV
         </strong>
         – For patients
         <strong>
          with
         </strong>
         chronic HBV, changing TDF to TAF with close renal monitoring may be considered since TDF and TAF are first-line treatment for HBV. However, the risk of continued renal dysfunction must be weighed against the potential benefits of TAF. Switching TDF to
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         is the other principal option to consider. The management of patients with HIV/HBV coinfection with reduced kidney function is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">
          "Treatment of chronic hepatitis B in patients with HIV", section on 'Renal insufficiency on tenofovir'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         It is important that antiretroviral-induced renal toxicity be differentiated from benign effects on estimated glomerular filtration rate (eGFR).
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          Rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ,
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , and bictegravir all block tubular secretion of creatinine, leading to an expected small increase in serum creatinine (and decrease in eGFR), which is noticeable in the first four to eight weeks of therapy [
         <a href="#rid92">
          92
         </a>
         ]. This change in eGFR is benign and does not warrant a change to ART; however, if the patient is also taking TDF, one must monitor for TDF toxicity (such as with regular urinalysis to screen for new proteinuria or glycosuria) [
         <a href="#rid93">
          93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy", section on 'ART-associated toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3522415817">
         <span class="h4">
          Kidney disease not related to ART
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients will have pre-existing kidney disease or develop new kidney disease not related to their ART regimen. In such patients, TDF should be avoided. TAF can be used for those with moderately reduced kidney function (eg, creatinine clearance between 30 to 60 mL/min). Alternatively, a tenofovir-sparing regimen may be reasonable for select patients. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3800784125">
         <span class="h3">
          Osteopenia/osteoporosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         TDF reduces bone mineral density more than other antiretroviral options [
         <a href="#rid5">
          5,94-97
         </a>
         ]. Thus, we switch patients with low bone density who are receiving a TDF-containing regimen to an alternative one [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         One option is to switch TDF to TAF since switching TDF to another agent may lead to improvement in bone mineral density [
         <a href="#rid7">
          7-10,89
         </a>
         ]; however, long-term post-switch data are lacking, especially for TAF. Another option is switching to an NRTI-sparing/limiting regimen, but this approach should only be used in select patients. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above.)
        </p>
        <p>
         In patients receiving a PI, consideration should also be given to switching the boosted PI to an alternate agent, such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir, if possible. Some studies have also implicated PIs in reducing bone mineral density [
         <a href="#rid5">
          5,94,97
         </a>
         ]. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          Efavirenz
         </a>
         affects vitamin D metabolism and reduces vitamin D levels, and switching efavirenz to an alternative drug may lead to increased vitamin D levels [
         <a href="#rid98">
          98-100
         </a>
         ]. However, the clinical benefit of switching for this indication has not been established.
        </p>
        <p class="headingAnchor" id="H479189092">
         <span class="h3">
          Chronic HBV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HIV/HBV coinfection, all efforts should be made to use a regimen that includes TAF or TDF. Patients with HIV/HBV who cannot take tenofovir as part of their regimen (eg, patients with a creatinine clearance below 30 mL/min) should be managed in consultation with an expert in HIV and viral hepatitis. (See
         <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">
          "Treatment of chronic hepatitis B in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1006638672">
         <span class="h3">
          Hyperlipidemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain antiretroviral agents affect lipids more than others [
         <a href="#rid101">
          101
         </a>
         ]. Boosted PIs and older NRTIs (eg,
         <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">
          zidovudine
         </a>
         ) are the worst offenders in terms of metabolic side effects. The NNRTI
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         also raises lipids, especially triglycerides. Thus, if a patient with significant hyperlipidemia is receiving one of these agents, we change to an alternative regimen if we can ensure virologic suppression will be maintained. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p>
         Among the integrase inhibitors, a nonboosted INSTI (
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or bictegravir) is preferred over cobicistat-boosted
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         if lipids are a concern. If an NNRTI is used,
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         or
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         is generally preferred over
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         . For patients who require a boosted PI,
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         and
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         are better than older PIs, such as lopinavir [
         <a href="#rid102">
          102,103
         </a>
         ]. Studies have found that there are benefits to changing from a boosted PI to bictegravir, dolutegravir, raltegravir, elvitegravir, rilpivirine, or doravirine [
         <a href="#rid103">
          103-110
         </a>
         ]. Updating efavirenz to newer options (eg, an INSTI, rilpivirine, or doravirine) can also lead to improvement [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
         TDF has lipid-lowering properties, though the clinical implications are unclear (especially because it tends to lower both low-density lipoprotein [LDL] and high-density lipoprotein [HDL]) [
         <a href="#rid113">
          113
         </a>
         ]. Although switching from TDF to TAF may lead to increased lipids because of lower circulating plasma tenofovir levels, this worsening is generally mild and the clinical significance is unknown [
         <a href="#rid7">
          7,8
         </a>
         ]. A switch from TDF to
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         can also lead to an increase in lipids [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         A more detailed discussion of how to manage cardiovascular risk in patients with HIV is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV", section on 'Role of antiretroviral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2445029323">
         <span class="h2">
          Reducing pill burden
         </span>
        </p>
        <p class="headingAnchor" id="H1572768044">
         <span class="h3">
          Single-pill regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients often inquire about switching to a single-pill regimen. Patients may be bothered by the number of pills they take, the frequency of dosing, and/or the size of the pill. Reducing pill burden promotes adherence and improves a patient's quality of life.
        </p>
        <p>
         Before switching to a single-pill option, we review resistance and virologic failure history and ensure that the new regimen will maintain virologic suppression. Many single-pill regimens fit the category of relatively low barrier to resistance (such as those that include an NNRTI or the INSTI
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ). Single-pill regimens that we consider to have high barrier to resistance include bictegravir-emtricitabine-TAF, darunavir-cobicistat-emtricitabine-TAF, and
         <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">
          dolutegravir-abacavir-lamivudine
         </a>
         . (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p>
         A potential concern when switching to a single-pill regimen is the large size of some of these tablets. Options that include TAF are smaller in size than options that include TDF or
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         . As an example, the
         <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">
          dolutegravir-abacavir-lamivudine
         </a>
         tablet is quite large. If feasible, it helps to show a patient the various pill sizes of the single-pill regimens and compare with the size of the two-tablet options to help inform the switch decision.
        </p>
        <p>
         Several clinical trials have examined switches to various single-pill regimens, and patients have generally maintained virologic suppression [
         <a href="#rid8">
          8,16,61,63,115-118
         </a>
         ]. Most of these trials have required enrollees to be taking their first or second ART regimen only, to have no history of virologic failure or drug resistance, and to have a suppressed viral load for a predefined period of time. However, we typically feel fine switching to
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         plus TAF-emtricitabine or to bictegravir-emtricitabine-TAF if a person has a routinely suppressed viral load, no INSTI resistance, and limited NRTI resistance mutations (such as only the M184V/I mutation). Emerging data suggest individuals with this resistance pattern can remain virologically suppressed after a switch to a bictegravir- or dolutegravir-containing regimen [
         <a href="#rid32">
          32,119
         </a>
         ].
        </p>
        <p>
         If switching to a single-pill regimen does not seem possible due to drug resistance, insurance barriers, or other concerns, other potential switches that can reduce pill burden or reduce dosing frequency include a shift from
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         to
         <a class="drug drug_general" data-topicid="98581" href="/z/d/drug information/98581.html" rel="external">
          darunavir-cobicistat
         </a>
         (assuming the individual is taking once-daily dosing darunavir); a change from once-daily boosted darunavir plus two NRTIs to darunavir-cobicistat-emtricitabine-TAF; simplification from
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         plus ritonavir to
         <a class="drug drug_general" data-topicid="99757" href="/z/d/drug information/99757.html" rel="external">
          atazanavir-cobicistat
         </a>
         ; or a switch from twice-daily
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         to the once-daily, high-dose option. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV", section on 'Raltegravir'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3657160908">
         <span class="h3">
          Long-acting injectable therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several two-drug regimens are available for maintenance ART, including an injectable regimen (
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         ), which is administered intramuscularly (IM) every four or every eight weeks [
         <a href="#rid120">
          120
         </a>
         ]. However, only certain patients are eligible for two-drug injectable therapy, as discussed above and in a separate topic review. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/138435.html" rel="external">
          "Use of long-acting cabotegravir-rilpivirine in people with HIV", section on 'Determining eligibility'
         </a>
         .)
        </p>
        <p>
         Injectable therapy may be a good option to replace oral therapy in select patients who have difficulty swallowing pills, difficulty storing their medications at home due to concerns around confidentiality or stigma, or a preference for nondaily dosing or injectable therapy. However, injectable therapy must be used with caution in patients who have not been adherent to their ART regimens or medical visits in the past; patients may experience prolonged periods of subtherapeutic ART levels if doses are missed, which puts them at risk for developing NNRTI and INSTI resistance. A more detailed discussion of long-acting
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         , including selecting eligible patients, is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/138435.html" rel="external">
          "Use of long-acting cabotegravir-rilpivirine in people with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1441422081">
         <span class="h2">
          Reducing drug-drug and drug-food interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some ART regimens may need to be modified to avoid drug-drug or drug-food interactions.
        </p>
        <p>
         The pharmacokinetic boosting agents
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         and
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         have more drug-drug interactions than other options because they inhibit cytochrome p450-mediated drug metabolism. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For a patient requiring regular intranasal or inhaled corticosteroids or corticosteroid injections, we generally avoid
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         or
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         in order to avoid potentially dangerous interactions. This requires selecting an active agent that does not require pharmacokinetic boosting, such as
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, for a patient with HIV/hepatitis C virus (HCV) coinfection, it is important to review interactions between antiretroviral agents and HCV direct-acting antivirals to ensure there are no significant interactions. In general, the unboosted integrase inhibitors
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , bictegravir, and
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         are the safest options. (See
         <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">
          "Treatment of chronic hepatitis C virus infection in the patient with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         and oral
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         require stomach acidity for maximal absorption. As a result, clinicians should avoid these agents in patients who require proton-pump inhibitors. While H2-blockers may sometimes be used if separated from rilpivirine or atazanavir by a specified number of hours, caution should still be employed with this strategy, and in this setting, we typically try to switch the antiretroviral agent if other effective options are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rifamycins carry a significant risk of drug-drug interactions.
         <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">
          Tenofovir disoproxil fumarate-emtricitabine
         </a>
         or
         <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">
          abacavir-lamivudine
         </a>
         can be used as the nucleoside combination when
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         is used (TAF should be avoided with rifampin).
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          Efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         are preferred as the third active drug; however, both raltegravir and dolutegravir require doubling of the daily dose when combined with rifampin. Bictegravir should not be combined with rifampin. Similarly,
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         should not be combined with rifampin, though it may be acceptable at a higher dose when combined with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         . More detailed information on drug interactions can be found in the
         <a class="external" href="/drug-interactions">
          drug interaction program
         </a>
         within UpToDate and in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The integrase inhibitors
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , and bictegravir all have potential interactions with cation-containing compounds (such as calcium or iron supplements and certain antacids and laxatives). The ART regimen and cation-containing compounds may need to be separated and should be reviewed. Specific information is in the drug information topics within UpToDate.
        </p>
        <p>
        </p>
        <p>
         Interactions can also be seen with psychiatric drugs, anti-epileptics, statins, agents that cause QTc prolongation, and others. Refer to the
         <a class="external" href="/drug-interactions">
          drug interaction program
         </a>
         within UpToDate to assess specific interactions.
        </p>
        <p>
         Some antiretroviral agents also have food requirements (eg, regimens containing oral
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         and regimens requiring boosting with
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         or
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         should be taken with food). If a patient is struggling with this requirement, a switch to an option that does not have food requirements (eg,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , bictegravir, or doravirine-based therapy) should be considered.
        </p>
        <p class="headingAnchor" id="H4078990484">
         <span class="h2">
          Cost or insurance coverage changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Changes in ART regimens may trigger insurance barriers or other challenges. As an example, they may cover bictegravir-TAF-emtricitabine, but not TAF-emtricitabine. Similarly, a patient's insurance coverage may change, resulting in one or more antiretroviral agents no longer being covered.
        </p>
        <p>
         In such situations, we generally petition the insurance company to provide the clinically optimal regimen. If this is not possible, we review the factors described above to find an alternative regimen that will be safe and effective. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1472407222">
         <span class="h1">
          PERSONS OF CHILDBEARING POTENTIAL/PREGANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         When switching a regimen in individuals who are of childbearing potential, it is important to determine if the person is pregnant, and if not, whether they are committed to using effective contraception (eg, oral, injectable, or intrauterine contraception). In persons who may conceive or who become pregnant and are taking an effective antiretroviral regimen, physicians must consider the risks and benefits of continuing the current regimen or making a switch and share these considerations with the patient. Detailed discussions of regimen selection and the safety of antiretroviral medications in these populations are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women", section on 'Individuals of childbearing potential'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">
          "Safety and dosing of antiretroviral medications in pregnancy", section on 'Integrase inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">
          "Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'ART selection and management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">
          "Prevention of vertical HIV transmission in resource-limited settings", section on 'Regimen management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H880056605">
         <span class="h1">
          LABORATORY MONITORING AFTER REGIMEN CHANGE
         </span>
         <span class="headingEndMark">
          —
         </span>
         After prescribing any new antiretroviral therapy (ART) regimen, we typically check in with the patient by phone after one to two days to confirm there were no pharmacy fill issues and they have received the new regimen correctly, and then we check in again after one to two weeks to ensure that the new regimen is well tolerated. We then recheck the HIV RNA along with a comprehensive metabolic panel four to eight weeks after the switch (four weeks preferred) [
         <a href="#rid11">
          11
         </a>
         ]. It is important to remember that certain agents, such as
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , and bictegravir, block tubular secretion of creatinine, and these agents can cause an expected mild rise in serum creatinine in the first four to eight weeks which should then stabilize. (See
         <a class="local">
          'Renal events due to ART regimen'
         </a>
         above.)
        </p>
        <p>
         In the absence of any new symptoms, laboratory abnormalities, or evidence of viral rebound at this initial post-switch check, clinical and laboratory monitoring of the patient may resume on a regularly scheduled basis. (See
         <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">
          "Patient monitoring during HIV antiretroviral therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H83888990">
         <span class="h1">
          CAN A PATIENT RESUME A PRIOR REGIMEN
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is common for patients to feel concerned that if they switch from an effective antiretroviral medication or regimen they can never switch back. In general, a change back to the pre-switch regimen is acceptable for virologically suppressed patients who were switched to reduce pill burden, improve mild side effects, or update or simplify the regimen. (See
         <a class="local">
          'Reasons for changing a regimen'
         </a>
         above.)
        </p>
        <p>
         One exception is a switch off the non-nucleoside transcriptase inhibitor (NNRTI)
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         . For patients with a high CD4 count (&gt;250 cells/microL for females, &gt;400 cells/microL for males), if we switch nevirapine to another option, we do not switch back to nevirapine if an equally effective regimen is available.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          Nevirapine
         </a>
         is contraindicated in treatment-naïve patients with a high CD4 count because of serious immune-mediated hepatotoxicity, and given the potential risk for severe toxicity, there are insufficient data to support switching back to nevirapine in such patients who are treatment experienced. In addition, a meta-analysis found an increased risk of hepatotoxicity leading to drug discontinuation among virologically suppressed patients who switched from a protease inhibitor (PI)-based regimen to a nevirapine-containing regimen when compared with those who stayed on their PI (pooled risk difference 7 percent; 95% CI 3-12 percent) [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3263089952">
         <span class="h1">
          INVESTIGATIONAL APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment options using agents with novel mechanisms of action are being examined. One approach is the use of broadly neutralizing monoclonal antibodies (bNAbs) as an alternative or an adjunct to antiretroviral therapy (ART) [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Early studies using bNAbs demonstrated the rapid selection of resistant HIV and viral rebound in the absence of suppressive ART [
         <a href="#rid123">
          123,124
         </a>
         ]. However, the field has advanced since then, and several other broadly neutralizing antibody approaches are under development or in clinical trials [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         The use of a bNAb that blocks the virus-binding site on human CD4 cells (UB-421) was evaluated in a nonrandomized trial of 29 patients taking ART with a CD4 count of &gt;350 cells/microL and a viral load of &lt;20 copies/mL [
         <a href="#rid126">
          126
         </a>
         ]. Patients received eight infusions of UB-421 dosed as either 10 mg/kg every week or 25 mg/kg every two weeks; ART was stopped one week after initiating UB-241 and resumed upon completion of the eighth dose. Patients maintained virologic suppression while receiving UB-241, although eight patients experienced viral blips (21 to 142 copies) of unclear significance. Rash was the most common adverse event but only led to treatment discontinuation in one person. Despite the antiviral activity of bNAbs demonstrated in these studies, there is no clear leading candidate or strategy for bNAb-based therapy, and their eventual role in clinical practice remains uncertain.
        </p>
        <p class="headingAnchor" id="H2623562959">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">
          "Society guideline links: HIV treatment in nonpregnant adults and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1900472081">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reasons for changing a regimen
         </strong>
         – For persons living with HIV who have a stably suppressed viral load (eg, at least 6 to 12 months) on antiretroviral therapy (ART), there are times when it may be reasonable to switch the ART regimen because of factors such as side effects, pill burden, new or worsening medical comorbidities, drug-drug interactions, or the risk of long-term toxicity. (See
         <a class="local">
          'Reasons for changing a regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation prior to switching
         </strong>
         – Prior to switching a regimen, it is important to evaluate the patient's antiretroviral history (especially history of any virologic failures, antiretroviral drug resistance, or antiretroviral drug intolerances), comorbid conditions, and barriers to taking the current regimen. If considering a switch off of
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) or
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF), it is especially important to review the hepatitis B status. (See
         <a class="local">
          'Evaluation prior to switching regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ensuring potency of the new regimen
         </strong>
         – In a patient who has a suppressed viral load, switching therapy can involve a single- or multi-drug switch. In either case, it is important to ensure that the new regimen will maintain virologic suppression. The likelihood that a patient will maintain virologic suppression depends upon prior resistance mutations and the new regimen's relative barrier to resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regimens with a relatively high barrier to resistance include the integrase inhibitors
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or bictegravir or a pharmacologically boosted protease inhibitor (PI). Regimens without one of the agents (eg, those that include
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         , or
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         with a nucleoside reverse transcriptase inhibitors [NRTI] combination) have a lower barrier to resistance. (See
         <a class="local">
          'Ensuring the potency of the new regimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional considerations when switching regimens
         </strong>
         – Additional considerations for regimen selection include ART-related side effects, risk of long-term toxicity, pill burden, and drug interactions. Other factors, such as cost, insurance access, food requirements, and the use of contraception in persons of childbearing potential, may also impact regimen selection. (See
         <a class="local">
          'Other considerations for regimen selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of two-drug oral or injectable therapy
         </strong>
         – In select patients with virologic suppression, certain two-drug regimens (eg,
         <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">
          dolutegravir-lamivudine
         </a>
         ,
         <a class="drug drug_general" data-topicid="115773" href="/z/d/drug information/115773.html" rel="external">
          dolutegravir-rilpivirine
         </a>
         , boosted
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         plus
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         , boosted darunavir plus
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or long-acting, injectable
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         ) can maintain virologic suppression. We typically consider a transition to one of these two-drug options in individuals if they have or are at risk for toxicity from NRTIs like TDF, TAF, or
         <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">
          abacavir
         </a>
         , assuming they have routinely undetectable HIV RNA levels, no hepatitis B coinfection, and no confirmed or suspected resistance to the two-drug regimen. (See
         <a class="local">
          'Eligibility for two-drug regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Injectable therapy may be ideally suited for eligible patients who have difficulty swallowing pills, difficulty storing their medications at home due to concerns around confidentiality or stigma, or a preference for nondaily dosing or injectable therapy. However, such patients must be able to commit to regular clinic visits for injections since patients may experience prolonged periods of subtherapeutic ART levels if doses are missed, which puts them at risk for developing non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase strand transfer inhibitor (INSTI) resistance. Use of long-acting
         <a class="drug drug_general" data-topicid="130321" href="/z/d/drug information/130321.html" rel="external">
          cabotegravir-rilpivirine
         </a>
         , including how to select eligible patients for this option, is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/138435.html" rel="external">
          "Use of long-acting cabotegravir-rilpivirine in people with HIV"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Carrero-Gras A, Antela A, Muñoz-Rodríguez J, et al. Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study. J Int AIDS Soc 2014; 17:19819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014; 70:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 2015; 60:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffi F, Orkin C, Clarke A, et al. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr 2017; 75:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016; 16:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negredo E, Domingo P, Pérez-Álvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother 2014; 69:3368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch M, Tong WW, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med 2014; 15:373.
          </a>
         </li>
         <li class="breakAll">
          Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [page H-22]. (Accessed on October 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023; 329:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS 2017; 31:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 2011; 6:e22003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arribas JR, Girard PM, Paton N, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med 2016; 17:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallant J, Sugarman J. Dolutegravir monotherapy: when should clinical practice be clinical research? Antivir Ther 2017; 22:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hocqueloux L, Raffi F, Prazuck T, et al. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clin Infect Dis 2019; 69:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meybeck A, Alidjinou EK, Huleux T, et al. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients. AIDS Patient Care STDS 2020; 34:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis KE, Nawas GT, Chan C, et al. Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment. Open Forum Infect Dis 2020; 7:ofz533.
          </a>
         </li>
         <li class="breakAll">
          Toma J, Tan Y, Cai S, et al. Drug resistance profiles derived from HIV-1 DNA in ARV suppressed patients correlate with historical resistance profiles obtained from HIV-1 plasma RNA. ICAAC 2015, September 17-21, 2015, San Diego.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saracino A, Gianotti N, Marangi M, et al. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol 2008; 80:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaugerre C, Braun J, Charreau I, et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med 2012; 13:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirden M, Soulie C, Valantin MA, et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother 2011; 66:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boukli N, Boyd A, Collot M, et al. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads. J Antimicrob Chemother 2018; 73:3129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diallo K, Murillo WE, de Rivera IL, et al. Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country. Int J Mol Epidemiol Genet 2012; 3:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis 2021; 73:e485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acosta RK, Willkom M, Andreatta K, et al. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir Immune Defic Syndr 2020; 85:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreatta K, Willkom M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother 2019; 74:3555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagins D, Kumar P, Saag M, et al. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr 2021; 88:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ombajo LA, Penner J, Nkuranga J, et al. Second-Line Switch to Dolutegravir for Treatment of HIV Infection. N Engl J Med 2023; 388:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf 2017; 16:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baril JG, Angel JB, Gill MJ, et al. Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS One 2016; 11:e0148231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girouard MP, Sax PE, Parker RA, et al. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clin Infect Dis 2016; 62:784.
          </a>
         </li>
         <li class="breakAll">
          Joly V, Burdet C, Landman R, et al. Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL trial. In: Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle. Abstract 458.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis 2018; 66:1794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother 2019; 74:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis 2020; 71:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gantner P, Cuzin L, Allavena C, et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med 2017; 18:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capetti AF, Sterrantino G, Cossu MV, et al. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. PLoS One 2016; 11:e0164753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulido F, Ribera E, Lagarde M, et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis 2017; 65:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Molina JA, Rubio R, Rivero A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother 2017; 72:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother 2017; 72:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinner CD, Kümmerle T, Schneider J, et al. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. Open Forum Infect Dis 2020; 7:ofaa356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggiolo F, Gianotti N, Comi L, et al. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). J Antimicrob Chemother 2020; 75:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquau J, de Jesus SE, Arazo P, et al. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study). BMC Infect Dis 2019; 19:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro J, González-Cordón A, Casado JL, et al. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. J Antimicrob Chemother 2020; 75:1955.
          </a>
         </li>
         <li class="breakAll">
          Denyer R, Zemsokova J, BeatyyD, et al. Dolutegravir and doravirine in combination: when standard antiretroviral regimens are unacceptable. Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S532–S533, https://doi.org/10.1093/ofid/ofaa439.1195.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MJ, Kim SW, Chang HH, et al. Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infect Chemother 2015; 47:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffi F, Esser S, Nunnari G, et al. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med 2016; 17 Suppl 5:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65:e118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS 2016; 30:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozniak A, Flamm J, Antinori A, et al. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clin Trials 2017; 18:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazanave C, Reigadas S, Mazubert C, et al. Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014. Open Forum Infect Dis 2015; 2:ofv018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sculier D, Gayet-Ageron A, Battegay M, et al. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis 2017; 17:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS 2016; 30:2831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother 2017; 72:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menard A, Montagnac C, Solas C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS 2017; 31:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cid-Silva P, Llibre JM, Fernández-Bargiela N, et al. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Basic Clin Pharmacol Toxicol 2017; 121:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS 2017; 31:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kheloufi F, Boucherie Q, Blin O, Micallef J. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect. AIDS 2017; 31:1775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheper H, van Holten N, Hovens J, de Boer M. Severe depression as a neuropsychiatric side effect induced by dolutegravir. HIV Med 2018; 19:e58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008; 22:1890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gowda C, Newcomb CW, Liu Q, et al. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. Open Forum Infect Dis 2017; 4:ofx012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo PH, Sun HY, Chuang YC, et al. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis 2020; 92:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake JE, Wu K, Bares SH, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis 2020; 71:e471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerchberger AM, Sheth AN, Angert CD, et al. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis 2020; 71:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taramasso L, Berruti M, Briano F, di Biagio A. The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen. AIDS 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erlandson KM, Carter CC, Melbourne K, et al. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis 2021; 73:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard MA, Cindi Z, Bradford Y, et al. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. Clin Infect Dis 2021; 73:e2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallon PW, Brunet L, Hsu RK, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc 2021; 24:e25702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surial B, Mugglin C, Calmy A, et al. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Ann Intern Med 2021; 174:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood J, Turner M, Bofill C, et al. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr 2017; 76:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mounzer K, Brunet L, Hsu R, et al. Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Res Hum Retroviruses 2021; 37:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llibre JM, Brites C, Cheng CY, et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis 2023; 76:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood BR, Huhn GD. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? Open Forum Infect Dis 2021; 8:ofab542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV 2022; 9:e474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Halloran JA, Sahrmann J, Parra-Rodriguez L, et al. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus. Clin Infect Dis 2022; 75:2060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozniak A, Arribas JR, Gathe J, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr 2016; 71:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karris MY. Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. AIDS Res Hum Retroviruses 2017; 33:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aloy B, Tazi I, Bagnis CI, et al. Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys? AIDS Rev 2016; 18:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev 2014; 16:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borges ÁH, Hoy J, Florence E, et al. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clin Infect Dis 2017; 64:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown TT, Ross AC, Storer N, et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011; 16:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther 2014; 19:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamzah L, Tiraboschi JM, Iveson H, et al. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). Antivir Ther 2016; 21:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calza L, Colangeli V, Manfredi R, et al. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2016; 71:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyle GJ, Andrade-Villanueva J, Girard PM, et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012; 17:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiang N, James M, Walters S, et al. Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study. HIV Med 2014; 15:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Biagio A, Riccardi N, Taramasso L, et al. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. Int J Antimicrob Agents 2016; 48:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake JE, McComsey GA, Hulgan T, et al. Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. Open Forum Infect Dis 2015; 2:ofv059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis 2014; 46:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masiá M, Martínez E, Padilla S, et al. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. J Antimicrob Chemother 2013; 68:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig 2015; 35:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr 2019; 81:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazzaro A, Cacciola EG, Borrazzo C, et al. Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, Mootsikapun P. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials 2016; 17:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta SK, Mi D, Moe SM, et al. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr 2013; 64:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohl DA, Bhatti L, Small CB, et al. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med 2016; 17:106.
          </a>
         </li>
         <li class="breakAll">
          Daar E, DeJesus E, Ruane P, et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir Alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults: Week 48 Results. Presented at ID Week. October 4-8, 2017; San Diego. Abstract LB-4.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arribas JR, DeJesus E, van Lunzen J, et al. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials 2017; 18:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills A, Crofoot G, Ortiz R, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials 2014; 15:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther 2017; 22:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis 2020; 71:1379.
          </a>
         </li>
         <li class="breakAll">
          FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv (Accessed on January 22, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Med 2008; 9:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahomed S, Garrett N, Baxter C, et al. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. J Infect Dis 2021; 223:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 2016; 375:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 2015; 7:319ra206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med 2019; 25:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CY, Wong WW, Tsai HC, et al. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med 2019; 380:1535.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3766 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25397563" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052632" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20384533" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Renal toxicity associated with tenofovir use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24958564" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19874178" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25609682" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recommendations for evaluation and management of bone disease in HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28272164" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26538525" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25125679" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24460797" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24460797" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25285539" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36454551" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28692532" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20074791" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24670520" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21811554" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26709605" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27977411" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dolutegravir monotherapy: when should clinical practice be clinical research?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30601976" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32049556" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31915714" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31915714" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18712823" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22416781" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21393164" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30137336" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22493752" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32668455" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32701823" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31430369" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34397746" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37342923" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Second-Line Switch to Dolutegravir for Treatment of HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28621159" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Dual antiretroviral therapy for HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26849060" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26658053" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26658053" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29293895" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476165" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31905383" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29310899" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28444816" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27741309" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020293" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27629070" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28093483" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26062880" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32965277" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32129855" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30819101" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32134108" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32134108" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26788406" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27714978" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24979445" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19647866" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24256630" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24195548" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21763935" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26684822" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28689453" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21593661" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26034768" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28683720" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824625" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27860104" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28333231" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Tolerability of integrase inhibitors in a real-life setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28441180" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28627771" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28692533" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Adverse events of raltegravir and dolutegravir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28700395" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28744997" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Severe depression as a neuropsychiatric side effect induced by dolutegravir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753871" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Exacerbation of depression associated with starting raltegravir: a report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28470014" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31884172" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32099991" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504324" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32028332" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33987636" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32829410" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33838004" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33721521" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28825943" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34002626" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35235656" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34877366" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35688166" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35521785" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26627107" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28403627" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27438578" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25350530" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25234519" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329090" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22301411" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22024522" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21606537" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24430534" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20588161" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26460504" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846208" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22388634" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25334035" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27566908" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26380350" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24161018" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23075691" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637061" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30985556" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35054243" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26739573" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24278992" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20495438" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26176344" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26176344" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28555519" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24710918" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28401876" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31606734" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31606734" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18651856" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32604408" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27959728" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26702094" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30936546" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30995373" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
